
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the Month of April 2018

Commission File Number: 001-38205

ZAI LAB LIMITED

(Translation of registrant's name into English)

**4560 Jinke Road, Bldg. 1, 4F, Pudong, Shanghai, China 201210
(Address of principal executive offices)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
Exhibit 99.1	Announcement related to announcement of 2017 financial results

SIGNATURES

Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ZAI LAB LIMITED

By: /s/ Billy Cho

Name: Billy Cho

Title: Chief Financial Officer

Dated: April 24, 2018



Zai Lab Limited to Announce Full Year 2017 Financial Results

SHANGHAI, China. April 24, 2018: Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that it will host a conference call and webcast on Wednesday, May 2nd, 2018 at 8:30am ET to discuss financial results for the full year ended December 31, 2017. On the call, Zai Lab's senior management team will also provide the latest status update on the Company's various development programs.

Investor Conference Call Details

Date: Wednesday, May 2nd, 2018

Time: 8:30am ET

Dial-In Details: 1-866-394-4355 (US); 1-314-888-4344 (International); 4006828609 (China)

Conference ID: 5836799

A live webcast and replay will be available on the Zai Lab investor website: <http://ir.zailaboratory.com>. Please note, on Monday, April 30th, 2018 Zai Lab intends to file its Form 20-F for the Year Ended December 31, 2017.

About Zai Lab

Zai Lab (NASDAQ: ZLAB) is a Shanghai-based innovative biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. The company's experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast growing segments of China's pharmaceutical market and global unmet medical needs. Zai Lab's vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners' and its own products in order to impact human health worldwide.

Contact:

Zai Lab

Billy Cho
+86 137 6151 2501
billy.cho@zailaboratory.com

Solebury Trout

John Graziano
+1 646 378 2942
jgraziano@troutgroup.com